GE Healthcare has announced plans to allocate $1 billion over five years to expand its diagnostic and imaging capabilities in oncology as well as to improve its manufacturing technologies. This will include new spending on biomarkers.
A service provider for the life science industry, Horizon Discovery Ltd, has completed the second closing of a Series C funding round, raising a total of £11.3 million via a private share placement. The round was led by MVM Life Sciences.
Oxford BioTherapeutics Ltd has formed a collaboration with Seattle Genetics Inc to jointly discover antibody-drug conjugates (ADC) for cancer. ADCs are antibodies attached by a linker to a cytotoxic drug and designed to kill cancer cells.
Newron Pharmaceuticals SpA is strengthening its ties with Merck Serono as the two companies seek to validate two new CNS compounds. The expanded collaboration was highlighted in Newron’s financial report for the 2011 first half.
.AM-Pharma BV of the Netherlands has raised €29.2 million under adverse financing conditions. The proceeds will allow it to test a recombinant form of alkaline phosphatase in patients with acute kidney injury (AKI) up to the completion of phase 2.
Celtic Pharma Holdings, a global private equity group, has launched a new company that will manufacture, register and commercialise products from the companies in its investment portfolio.
Pharnext SAS of France, which is developing new combinations of previously registered medicines, has raised an initial €2.5 million in a new funding round in order to finance the clinical development of a product for Charcot-Marie-Tooth disease.
A Belgian start-up ophthalmology company, Amakem NV, has raised €18 million in a Series A round to progress its lead product for glaucoma into a clinical proof-of-concept study. The round was led by Forbion Capital Partners.
Aleva Neurotherapeutics SA of Lausanne, Switzerland has raised €9.5 million in a Series A round to support development of its implant technology for deep brain stimulation which would complement drug therapy for major neurological disorders.
A new UK spin-out dedicated to the technology of DNA repair has received £6 million in Series A funding from a venture capital syndicate led by Sofinnova Partners. The technology comes from the laboratory of Prof Stephen Jackson.